Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.18 CHF | -1.36% | +6.04% | +105.66% |
Sales 2024 * | 36.98M 40.23M 35.89M | Sales 2025 * | 27.02M 29.4M 26.22M | Capitalization | 199M 216M 193M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.32M 14.56M | Net income 2025 * | 5M 5.44M 4.85M | EV / Sales 2024 * | 5.97 x |
Net Debt 2024 * | 22.05M 24M 21.4M | Net cash position 2025 * | 7M 7.62M 6.79M | EV / Sales 2025 * | 7.09 x |
P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
36.3
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.57% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | -1.36% | ||
1 week | +6.04% | ||
Current month | +1.80% | ||
1 month | +1.80% | ||
3 months | +28.86% | ||
6 months | +123.25% | ||
Current year | +105.66% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 10.18 | -1.36% | 21 692 |
24-06-04 | 10.32 | -0.77% | 55,833 |
24-06-03 | 10.4 | +4.00% | 81,868 |
24-05-31 | 10 | +2.99% | 72,653 |
24-05-30 | 9.71 | +1.15% | 41,890 |
Delayed Quote Swiss Exchange, June 05, 2024 at 08:36 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+105.66% | 216M | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
+64.51% | 26.38B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+7.19% | 9.25B |
- Stock Market
- Equities
- NWRN Stock